Genfarma High-Tech Pharmaceutical Joint Stock Company officially received the Good Manufacturing Practice Certificate (GMP) issued by the Drug Administration of Vietnam - Ministry of Health. Not only marking the factory meeting international standards for drug production, the event also opens up a new development phase in Vietnam's journey to build biotechnology capacity, with the orientation of gradually mastering monoclonal antibody technology - the foundation of many modern treatments in the world.
For many years, biological drugs, especially drugs for cancer and autoimmune diseases based on monoclonal antibody technology, have mainly depended on imports at high costs. The development of domestic research and production capacity is considered one of the important conditions to improve the autonomy of the pharmaceutical industry, while expanding opportunities to access advanced therapies for patients.
For Genfarma, the GMP certification is the foundation for realizing that goal.
Mr. Bui Le Khoa, General Director of Genfarma, said: "GMP is a necessary condition for a modern pharmaceutical enterprise. What we aim for is to gradually master advanced biotechnology, develop products that meet international standards and contribute to bringing more high-quality treatment options for patients. We believe that investing in technology, research and people is the foundation for building sustainable competitiveness.
Genfarma Pharmaceutical Plant is synchronously invested according to WHO-GMP standards, EU-GMP orientation with a modern production, testing, storage and research and development (R&D) center system. The system is designed in the direction of automation, integrating data management and meeting international standards for data integrity, creating a platform for developing biopharmaceutical products with high technical requirements.
In parallel with infrastructure investment, Genfarma focuses on developing research capacity and technology transfer. In 2025, the enterprise received the transfer of pharmaceutical production technology from BioCubaFarma, one of Cuba's leading biotechnology corporations. This cooperation opens up opportunities to access advanced technologies in the field of biomedical drugs, especially products for cancer treatment and many complex diseases.
The receipt of GMP certification therefore not only confirms the production capacity of a factory, but also marks a shift from infrastructure investment to building technological capacity - a factor that determines the long-term competitiveness of enterprises in the biopharmaceutical sector.
GMP certification marks a new step in Genfarma's development to produce advanced, high-quality biotechnology products. This is not only a meaningful event for businesses and patients, but also contributes to improving the competitiveness of Vietnam's pharmaceutical industry, promoting the development of the pharmaceutical industry towards modernization and gradually mastering high technology." - a representative of the Drug Administration of Vietnam shared.
In the coming time, Genfarma will continue to invest in research, human resource development and expand international cooperation to gradually complete the pharmaceutical product value chain in Vietnam. A representative of the company said that the goal is not only to produce products that meet international standards but also to contribute to forming a modern biotechnology platform, improving the autonomy capacity of the pharmaceutical industry and promoting the innovation ecosystem in the healthcare sector.
